M-A: non-invasive tests for advanced fibrosis can reduce the need for biopsy in patients with non-alcoholic fatty liver disease.
2 Sep, 2021 | 08:14h | UTC
Commentary on Twitter
The long, winding and expensive road leading to highly sensitive and specific noninvasive Dx of #NASH @Gut_BMJ https://t.co/ToIkF3yTAU
— Daniel J Drucker (@DanielJDrucker) May 25, 2021